GPC3-CAR-T cells have been shown to be capable of eliminating GPC3+ HCC cells and tumors in a patient-derived xenograft [185] and in a phase I clinical study demonstrated safe and potential effectiveness in patients with advanced GPC3+ HCC [186]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.